INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 160 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $277,822 | +141.4% | 14,985 | +44.0% | 0.00% | – |
| Q2 2023 | $115,068 | -18.3% | 10,404 | +3.1% | 0.00% | – |
| Q3 2022 | $140,756 | -1.4% | 10,090 | -2.4% | 0.00% | – |
| Q2 2022 | $142,713 | -21.2% | 10,334 | -7.2% | 0.00% | – |
| Q1 2022 | $181,085 | -23.3% | 11,130 | -23.3% | 0.00% | – |
| Q4 2021 | $236,000 | -0.8% | 14,506 | -9.4% | 0.00% | – |
| Q3 2021 | $238,000 | -27.4% | 16,005 | -2.7% | 0.00% | – |
| Q2 2021 | $328,000 | -7.9% | 16,446 | +6.6% | 0.00% | – |
| Q1 2021 | $356,000 | -8.7% | 15,434 | -2.3% | 0.00% | – |
| Q4 2020 | $390,000 | -38.6% | 15,801 | +3.1% | 0.00% | -100.0% |
| Q3 2020 | $635,000 | -12.7% | 15,328 | -1.5% | 0.00% | 0.0% |
| Q2 2020 | $727,000 | -28.4% | 15,568 | -3.6% | 0.00% | 0.0% |
| Q1 2020 | $1,016,000 | -46.4% | 16,142 | +5.6% | 0.00% | -50.0% |
| Q4 2019 | $1,894,000 | +89.6% | 15,284 | -1.9% | 0.00% | +100.0% |
| Q3 2019 | $999,000 | -18.8% | 15,580 | +0.7% | 0.00% | 0.0% |
| Q2 2019 | $1,231,000 | -23.8% | 15,466 | +7.1% | 0.00% | -50.0% |
| Q1 2019 | $1,615,000 | +19.5% | 14,440 | +7.6% | 0.00% | 0.0% |
| Q4 2018 | $1,352,000 | -25.2% | 13,415 | -6.2% | 0.00% | 0.0% |
| Q3 2018 | $1,807,000 | +26.7% | 14,300 | -15.9% | 0.00% | 0.0% |
| Q2 2018 | $1,426,000 | +1385.4% | 17,003 | +985.8% | 0.00% | – |
| Q1 2018 | $96,000 | +108.7% | 1,566 | +100.3% | 0.00% | – |
| Q4 2017 | $46,000 | +4.5% | 782 | +2.4% | 0.00% | – |
| Q3 2017 | $44,000 | -51.1% | 764 | +2.7% | 0.00% | – |
| Q2 2017 | $90,000 | +15.4% | 744 | +7.4% | 0.00% | – |
| Q1 2017 | $78,000 | +4.0% | 693 | 0.0% | 0.00% | – |
| Q4 2016 | $75,000 | -34.2% | 693 | 0.0% | 0.00% | – |
| Q3 2016 | $114,000 | +23.9% | 693 | +6.9% | 0.00% | – |
| Q2 2016 | $92,000 | +12.2% | 648 | -1.1% | 0.00% | – |
| Q1 2016 | $82,000 | -14.6% | 655 | +1.4% | 0.00% | – |
| Q4 2015 | $96,000 | -10.3% | 646 | 0.0% | 0.00% | – |
| Q3 2015 | $107,000 | -31.8% | 646 | -0.6% | 0.00% | – |
| Q2 2015 | $157,000 | -7.1% | 650 | +8.7% | 0.00% | – |
| Q1 2015 | $169,000 | +81.7% | 598 | 0.0% | 0.00% | – |
| Q4 2014 | $93,000 | -29.5% | 598 | +7.0% | 0.00% | – |
| Q3 2014 | $132,000 | -0.8% | 559 | -0.9% | 0.00% | – |
| Q2 2014 | $133,000 | -93.0% | 564 | -90.2% | 0.00% | -100.0% |
| Q1 2014 | $1,897,000 | +373.1% | 5,752 | -2.0% | 0.00% | +200.0% |
| Q4 2013 | $401,000 | +6.4% | 5,869 | +7.4% | 0.00% | 0.0% |
| Q3 2013 | $377,000 | +53.3% | 5,466 | -0.7% | 0.00% | – |
| Q2 2013 | $246,000 | – | 5,506 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |